Paper Details
- Home
- Paper Details
The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
Author: AlqaidAmmar, DickRizcallah, DoukkyRami, Morales DemoriRaysa, RangelMaria Octavia, WassoufMarwan
Original Abstract of the Article :
BACKGROUND: There has not been any prospective evaluation of the safety and tolerability of regadenoson (REG)-stress in patients with end-stage renal disease (ESRD). METHODS: From the pooled database of two identically designed randomized, double-blinded, placebo-controlled clinical trials, ASSUAGE...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1007/s12350-012-9654-2
データ提供：米国国立医学図書館（NLM）
Regadenoson in End-Stage Renal Disease: A Safe and Tolerable Option for Stress Testing
Stress tests are essential tools in diagnosing and managing heart disease. But for patients with end-stage renal disease (ESRD), finding safe and effective stress testing options can be challenging. Imagine a desert where the terrain is treacherous, and navigating can be risky. This study explores the safety and tolerability of regadenoson (REG), a medication used to stimulate blood flow during stress tests, in patients with ESRD. The researchers analyzed data from two clinical trials, comparing the incidence of adverse effects and hemodynamic responses to REG in patients with ESRD and healthy controls. This research offers valuable insights into the use of REG for stress testing in patients with ESRD, providing a potential solution for this challenging population.
Regadenoson: A Safe and Tolerable Option for Stress Testing in ESRD
The study's findings suggest that REG is a safe and tolerable option for stress testing in patients with ESRD, demonstrating a similar safety profile to that observed in healthy individuals. The researchers found no significant difference in the incidence of adverse effects between the two groups, reassuring healthcare providers about the potential use of REG in this population. This is like discovering a hidden oasis in the desert of stress testing options, providing a safe and effective path for diagnosing and managing heart disease in patients with ESRD.
Navigating Stress Testing in ESRD
This research emphasizes the importance of finding safe and effective diagnostic tools for patients with ESRD. It's a reminder that the journey towards better healthcare requires constant innovation and a commitment to finding solutions for all patients. The study highlights the need for further research to explore the optimal use of REG in this population and understand its long-term effects.
Dr. Camel's Conclusion
This research is a testament to the ongoing search for safe and effective treatments for patients with ESRD. Regadenoson offers a potential solution for stress testing in this population, opening new avenues for diagnosis and management of heart disease. It's a reminder that the journey towards better healthcare is a continuous quest, fueled by innovation and a commitment to improving patient care.
Date :
- Date Completed 2013-08-30
- Date Revised 2021-10-21
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.